INTRODUCTION
============

Neuroblastic tumors were described by Wright in 1910 and originate from indiferentiated nervous cells from the neural crest, present at the adrenal medulla, sympathetic ganglia and plexus. For this reason, they can grow in various parts of the body, being 48% adrenal, 25% retroperitoneal, 16% thoracic and are rarer on the neck and pelvis[@B1] ^,^ [@B2] ^,^ [@B3] ^,^ [@B4] ^,^ [@B11] ^,^ [@B17]. The etiology of neuroblastoma is unknown, but it seems to be related to congenital and genetic anomalies[@B4] ^,^ [@B7] ^,^ [@B10].

Neuroblastoma is the most common extracranial solid tumor in children and represents 10% of childhood cancers (one case for each 7000 children born) and 15% of pediatric cancer deaths[@B15] ^,^ [@B17]. In São Paulo State, Brazil, it represents 7.7 cases per million children, 30% having until one year of age and 90% aged until 19 months[@B3] ^,^ [@B4] ^,^ [@B7] ^,^ [@B8].

They are heterogeneous tumors that can maturate espontaneously or be highly indifferentiated, depending on the biology of the tumor. Thus, biological and molecular factors are related to clinical presentation and prognosis[@B2] ^,^ [@B3] ^,^ [@B5] ^,^ [@B9]. Signs and symptoms depend on tumor site, but these tumors envolve the main vascular trunks of the body and are often metastatic at diagnosis. Surgical ressection can be very challenging and severe complications can occur, although complete resection is the aim of the surgery. On the other hand, complete resection is often related to favorable histology[@B7] ^,^ [@B11] ^,^ [@B15]. Clinical symptoms may also be related to catecolamines and VIP producted by the tumor[@B3] ^,^ [@B4] ^,^ [@B7] ^,^ [@B17]. Image studies are essential for staging and determination of the primary tumor site[@B2] ^,^ [@B3] ^,^ [@B4]and diagnosis is made through tumor biopsy or bone marrow infiltration of neuroblasts[@B7] ^,^ [@B10].

Staging determine risk groups and individual treatment and several systems were proposed. In 1988, INSS *(International*Neuroblastoma Staging System) was presented as a common language for neuroblastoma staging, but it is made postoperatively and dependent on surgical expertise. So, in 2009 the *International*Neuroblastoma Risk Group (INRG) established a new staging system: INRGSS - *International* Neuroblastoma Risk Group Staging System, that evaluates the initial images at diagnosis and describes more than 20 risk factors, the IDRFs -*Image-Defined*Risk Factors*, that predicts surgical risks and challenges for complete resection at diagnosis* [@B2] ^,^ [@B6] ^,^ [@B7] ^,^ [@B8] ^,^ [@B13] ^,^ [@B14] ^,^ [@B15].

The presence of IDRFs is related to surgical complications and incomplete resections and literature uses this in order to equalize the type of resections among different institutions in the world[@B2] ^,^ [@B5] ^,^ [@B6] ^,^ [@B9] ^,^ [@B13].

The aim of this study was to compare the traditional resectability criteria (INSS) with the image risk factors criteria (IDRF) for resectability, in two moments: at diagnosis and preoperatively after chemotherapy in a reference institution for pediatric cancer in Brazil.

METHOD
======

This is a retrospective review of patients with neuroblastoma treated at the Pediatric Oncology Institute - GRAACC - UNIFESP from 2000 to 2015. Inclusion criteria were: patients with abdominal and pelvic neuroblastomas stages 3 and 4 that had images at diagnosis and before surgery. From 198 patients treated for neuroblastic tumors in the observation period, 64 met the inclusion criteria, but 25 were excluded because images could not be found, nine were referred to the institution after surgery elsewhere and three were initially diagnosed as renal tumors. Thus 27 patients were included in the study and clinical data were collected. Images at diagnosis and post-chemotherapy before surgery were reviewed by surgeons and radiologists. The aim was to evaluate resectability at diagnosis and after chemotherapy based on the presence of IDRFs described by Brisse *et al* (2009) as part of the INRGSS staging system and to determine if the system would impact the surgical decision made for each patient using INSS.

Statistical analysis
--------------------

SPSS 20.0 and STATA 12 were used; 5% significance was considered. Kappa and McNemar coeficients were used to compare resectability at diagnosis and post-chemotherapy between INSS and IDRF systems. Uni and multivariate analysis Kaplan-Meier curves and Cox regression models were done.

RESULTS
=======

Data from 27 children were analyzed. Age varied from 0-9 years, mean 2.5 years, median two years. Mean time from begining of symptoms and diagnosis was 1.4 year; 51.9% were females; 55.6% were aged more than 18 months at disgnosis; 66.7% were stage 4, and it was also verified, similar participations by location of the tumor (p=0,895, [Table 1](#t1){ref-type="table"})

TABLE 1Patients characteristics n%Gender27100.0Female1451.9Male1348.1Age27100.0\<12 months933.312 - 18 months311.1\> 18 months1555.6Stage27100.03933.341866.7Site27100.0Right adrenal829.6Left adrenal933.3Retroperitoneal1037.0Histology27100.0Unfavorable311.1Favorable725.9\*Missing1763.0\*(diagnosis by bone marrow) Initial approach27100.0Chemotherapy2696.3Surgery13.8Surgery (post-chemotherapy)26100.0No934.6Yes1765.4Surgical Resection17100.0Complete1058.8Incomplete741.2Complications27100.0No1659.3Yes13.7No surgery1037.0Status27100.0Alive without disease1451.9Alive with disease (in treatment)27,4Alive with disease (bone marrow transplantation)27.4Deceased933.3Recurrence27100.0No2281.5Yes518.5[^2]

TABLE 2Comparison between INSS and IDRFsINSSn%Resectable at diagnosis27100.0No2696.3Yes13.7Resectable after chemotherapy26100.0No1038.5Yes1661.5IDRFsN%Resectable at diagnosis27100.0No2385.2Yes414.8Resectable after chemotherapy26100.0No1765.4Yes934.6

As for compared resectability between INSS and IDRFs at diagnosis (Kappa=0,362, p=0,007) and after chemotherapy (Kappa=0,354, p=0,019), fragile but significant agreement results were observed. But when comparing results between diagnosis and post-chemotherapy using IDRFs, no agreement was observed (Kappa=0,194, p=0,107). For the INSS criteria it was not possible to calculate Kappa coefficient because all 26 patients were considered unresectable at diagnosis ([Figure 1](#f1){ref-type="fig"}).

FIGURE 1Concordance and Kappa values

As for the type of surgical resection at diagnosis and post-chemotherapy, for both INSS and IDRFs there was association for the type of resection post-chemotherapy on IDRF(p=0,001), meaning that all patients considered resectable post-chemotherapy by IDRFs had complete resections. On the other hand, 87.5% of patients considered unresectable had incomplete resections ([Table 3](#t3){ref-type="table"}).

TABLE 3Resectability: INSS/IDRFs, at diagnosis and post-chemotherapyResectabilityType of resectionTotalpCompleteIncomplete INSSn%n%n%At diagnosis1058.8741.217100.01.000No956.3743.816100.0 Yes1100.000.01100.0 Post-cheomtherapy956.3743.816100.0-No\-\-\-\-\-- Yes956.3743.816100.0 IDRFsn n n pAt diagnosis1058.8741.217100.00.603No753.8646.213100.0 Yes375.0125.04100.0 Post-chemotherapy956.3743.816100.00.001No112.5787.58100.0 Yes8100.000.08100.0 [^3]

On the ROC curve, a cut point of 1 on the post-chemotherapy IDRF was associated with 87.5% sensitivity and 66.7% of especificity for incomplete resection. Thus, if all post-chemotherapy patients with one or more IDRFs were classified as incomplete resections, 87.5% would be correctly classified and if classified as complete resections, 66.7% would be correctly classified ([Figure 2](#f2){ref-type="fig"}).

FIGURE 2ROC curve for complete resections; IDRFs in incomplete resections

For patients who had surgery after chemotherapy (n=16), differences were observed among number of IDRFs and complete or incomplete resections (p=0,009). The median number of IDRFs was lower for patients that had complete resections.

Survival was impacted by the number of IDRFs. The more IDRFs, the worse was the survival ([Figure 3](#f3){ref-type="fig"}).

FIGURE 3Number of IDRFs and survival

77.8% (n=18 patients) are alive and there is similar distribution on stages 3 and 4. Four patients are in treatment, 14 are out of treatment: one had complete response and did not have surgery, seven had complete resections, two remain with unresectable tumors after chemotherapy and four had incomplete resections. Nine died, all of them stage 4: eight for progression of disease and one for chemotoxicity.

DISCUSSION
==========

Neuroblastoma is a heterogeneous and multifactorial malignancy and its biology impacts survival rates. Multimodal treatment has enhanced the chances of survival and cure[@B8].

Literature shows predominance of males, but in the present series, 51.9% of patients were female (p=0.188). Gender had no influence on survival[@B5] ^,^ [@B13] ^,^ [@B17] ^,18^. On the other hand, age at diagnosis of more than 18 months is an independent risk factor for prognosis[@B5] ^,^ [@B9]. 55.6% were older than 18 months in this series (mean 30 months), showing the prevalence of high staged tumors.

Concerning site, 62.9% were adrenal, but had no impact on survival (p=0.266).

Surgery is the best initial approach in localized disease, but there is discussion about which is the best to do initially in bigger tumors that encase other structures and advanced staged tumors. The type of surgical resection and staging influence prognosis and some groups advocate complex and risky resections. But others say that aggressive surgery is questionable and has little benefit in high risk patients heavily treated with the multimodal treatment[@B6] ^,^ [@B17].

Preoperative chemotherapy is of essence in neuroblastomas that envolve renal vessels, celiac trunk or SMA, after which complete resection possibilities can enhance. Nephrectomies should be prevented, when possible[@B5] ^,^ [@B8] ^,^ [@B9].

Mullassery *et al* did a systematic review on the impact of aggressive surgery in stages 3 and 4 neuroblastomas. Complete resections are associated with better prognosis for stage 3, but have limited impact in stage 4 tumors.

Irtan *et al* compared images from the diagnosis and preoperatively, with the identification of IDRFs in both moments, along with the site and extent of the tumor and the local impact of chemotherapy for surgery. Resectability was enhanced by chemotherapy when using IDRFs: 14.8% at diagnosis and 34.6% after chemotherapy. In our series, post-chemotherapy IDRFs and the type of surgical resection were convergent since patients classified as resectable in the new criteria were actually resected in the past (p=0.001). For those considered unresectable, 87.5% had incomplete resections.

In a previous study at the same institution in 1998, severe surgical complications occurred in 16.4% with 30.7% mortality[@B1], but with the advances in chemotherapy, support care and bone marrow transplantation the present series had only one patient with surgical complication and the overall survival that used to be 49.4% is 66.6% today[@B1].

Of 17 patients with high stage disease treated with surgery, only one post-chemotherapy patient had a surgical complication (hemorrhage). This patient had six IDRFs at diagnosis and two IDRFs after chemotherapy, which correlates to challenges in surgery and incomplete resection, which he had.

The low incidence of surgical complications described, even in high stage disease, can be explained by the fact that the institution is reference for pediatric cancer in Brazil and also the use of preoperative chemotherapy, which reduces the number of IDRFs.

There have been changes in treatment protocols throughout the years and the relapse rate was 18.5%, lower than related in literature. Survival rates are comparable to those described in the literature (66.6%)[@B1] ^,^ [@B14].

There are several limitations in this study; it represents casuistic of a single institution; is retrospective; has a limited number of cases; and the biology of the tumor was not analyzed. Further prospective studies should be conducted to better compare INSS with INRGSS.

CONCLUSION
==========

Resectability was similar using INSS and IDRFs systems at diagnosis and post-chemotherapy. Chemotherapy enhances the resectability (14.8-34.6%) for the numbers if IDRFs decline. The presence of at least one IDRF was associated with incomplete resections and there was only one surgical complication and low relapse rate.
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